Advaxis Inc. (NASDAQ:ADXS) shares fell 3.2% during trading on Tuesday . The stock traded as low as $7.50 and last traded at $7.55, with a volume of 406,438 shares traded. The stock had previously closed at $7.80.

Several brokerages have commented on ADXS. Jefferies Group restated a “buy” rating on shares of Advaxis in a report on Friday, June 10th. HC Wainwright reiterated a “buy” rating on shares of Advaxis in a research note on Wednesday, June 29th. Finally, FBR & Co reiterated an “outperform” rating and issued a $34.00 price target on shares of Advaxis in a research note on Thursday, July 7th. Six equities research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $24.80.

The company’s 50 day moving average is $8.48 and its 200 day moving average is $8.00. The stock’s market cap is $259.66 million.

In other Advaxis news, Director Thomas J. Mckearn sold 4,100 shares of the business’s stock in a transaction dated Friday, May 13th. The stock was sold at an average price of $7.45, for a total transaction of $30,545.00. Following the completion of the sale, the director now owns 82,120 shares of the company’s stock, valued at $611,794. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Daniel O’connor sold 8,237 shares of the business’s stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $7.51, for a total value of $61,859.87. Following the sale, the chief executive officer now directly owns 316,661 shares of the company’s stock, valued at approximately $2,378,124.11. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Advaxis stock. Oxford Asset Management bought a new stake in Advaxis Inc. (NASDAQ:ADXS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 146,282 shares of the biotechnology company’s stock, valued at approximately $1,502,000. Oxford Asset Management owned 0.43% of Advaxis as of its most recent SEC filing.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.